294 related articles for article (PubMed ID: 22663067)
1. Liberation of copper from amyloid plaques: making a risk factor useful for Alzheimer's disease treatment.
Geng J; Li M; Wu L; Ren J; Qu X
J Med Chem; 2012 Nov; 55(21):9146-55. PubMed ID: 22663067
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Aβ peptide aggregation by ruthenium(II) polypyridyl complexes through copper chelation.
Peng YB; Tao C; Tan CP; Zhao P
J Inorg Biochem; 2021 Nov; 224():111591. PubMed ID: 34450410
[TBL] [Abstract][Full Text] [Related]
3. Design, selection, and characterization of thioflavin-based intercalation compounds with metal chelating properties for application in Alzheimer's disease.
Rodríguez-Rodríguez C; Sánchez de Groot N; Rimola A; Alvarez-Larena A; Lloveras V; Vidal-Gancedo J; Ventura S; Vendrell J; Sodupe M; González-Duarte P
J Am Chem Soc; 2009 Feb; 131(4):1436-51. PubMed ID: 19133767
[TBL] [Abstract][Full Text] [Related]
4. Multitarget-directed benzylideneindanone derivatives: anti-β-amyloid (Aβ) aggregation, antioxidant, metal chelation, and monoamine oxidase B (MAO-B) inhibition properties against Alzheimer's disease.
Huang L; Lu C; Sun Y; Mao F; Luo Z; Su T; Jiang H; Shan W; Li X
J Med Chem; 2012 Oct; 55(19):8483-92. PubMed ID: 22978824
[TBL] [Abstract][Full Text] [Related]
5. The heterogeneous nature of Cu2+ interactions with Alzheimer's amyloid-β peptide.
Drew SC; Barnham KJ
Acc Chem Res; 2011 Nov; 44(11):1146-55. PubMed ID: 21714485
[TBL] [Abstract][Full Text] [Related]
6. RTHLVFFARK-NH
Meng J; Zhang H; Dong X; Liu F; Sun Y
J Inorg Biochem; 2018 Apr; 181():56-64. PubMed ID: 29407908
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and biological evaluation of curcumin analogues as multifunctional agents for the treatment of Alzheimer's disease.
Chen SY; Chen Y; Li YP; Chen SH; Tan JH; Ou TM; Gu LQ; Huang ZS
Bioorg Med Chem; 2011 Sep; 19(18):5596-604. PubMed ID: 21840724
[TBL] [Abstract][Full Text] [Related]
8. Gold nanoparticle-capped mesoporous silica-based H
Yang L; Yin T; Liu Y; Sun J; Zhou Y; Liu J
Acta Biomater; 2016 Dec; 46():177-190. PubMed ID: 27619837
[TBL] [Abstract][Full Text] [Related]
9. N,N'-1,10-Bis(Naringin) Triethylenetetraamine, Synthesis and as a Cu(II) Chelator for Alzheimer's Disease Therapy.
Guo LX; Sun B
Biol Pharm Bull; 2021 Jan; 44(1):51-56. PubMed ID: 33162492
[TBL] [Abstract][Full Text] [Related]
10. A new water-soluble Cu(II) chelator that retrieves Cu from Cu(amyloid-β) species, stops associated ROS production and prevents Cu(II)-induced Aβ aggregation.
Noël S; Perez F; Pedersen JT; Alies B; Ladeira S; Sayen S; Guillon E; Gras E; Hureau C
J Inorg Biochem; 2012 Dec; 117():322-5. PubMed ID: 22819647
[TBL] [Abstract][Full Text] [Related]
11. Chiral metallohelical complexes enantioselectively target amyloid β for treating Alzheimer's disease.
Li M; Howson SE; Dong K; Gao N; Ren J; Scott P; Qu X
J Am Chem Soc; 2014 Aug; 136(33):11655-63. PubMed ID: 25062433
[TBL] [Abstract][Full Text] [Related]
12. Chelation and intercalation: complementary properties in a compound for the treatment of Alzheimer's disease.
Cherny RA; Barnham KJ; Lynch T; Volitakis I; Li QX; McLean CA; Multhaup G; Beyreuther K; Tanzi RE; Masters CL; Bush AI
J Struct Biol; 2000 Jun; 130(2-3):209-16. PubMed ID: 10940226
[TBL] [Abstract][Full Text] [Related]
13. Copper(II)-chelating homocarnosine glycoconjugate as a new multifunctional compound.
Grasso GI; Arena G; Bellia F; Rizzarelli E; Vecchio G
J Inorg Biochem; 2014 Feb; 131():56-63. PubMed ID: 24246303
[TBL] [Abstract][Full Text] [Related]
14. Targeting the neurotoxic species in Alzheimer's disease: inhibitors of Abeta oligomerization.
De Felice FG; Vieira MN; Saraiva LM; Figueroa-Villar JD; Garcia-Abreu J; Liu R; Chang L; Klein WL; Ferreira ST
FASEB J; 2004 Sep; 18(12):1366-72. PubMed ID: 15333579
[TBL] [Abstract][Full Text] [Related]
15. New cyclodextrin-bearing 8-hydroxyquinoline ligands as multifunctional molecules.
Oliveri V; Puglisi A; Viale M; Aiello C; Sgarlata C; Vecchio G; Clarke J; Milton J; Spencer J
Chemistry; 2013 Oct; 19(41):13946-55. PubMed ID: 24038335
[TBL] [Abstract][Full Text] [Related]
16. Characterization of new specific copper chelators as potential drugs for the treatment of Alzheimer's disease.
Nguyen M; Robert A; Sournia-Saquet A; Vendier L; Meunier B
Chemistry; 2014 May; 20(22):6771-85. PubMed ID: 24797103
[TBL] [Abstract][Full Text] [Related]
17. Tripeptide GGH as the Inhibitor of Copper-Amyloid-β-Mediated Redox Reaction and Toxicity.
Hu X; Zhang Q; Wang W; Yuan Z; Zhu X; Chen B; Chen X
ACS Chem Neurosci; 2016 Sep; 7(9):1255-63. PubMed ID: 27433833
[TBL] [Abstract][Full Text] [Related]
18. Pt(II) compounds interplay with Cu(II) and Zn(II) coordination to the amyloid-β peptide has metal specific consequences on deleterious processes associated to Alzheimer's disease.
Collin F; Sasaki I; Eury H; Faller P; Hureau C
Chem Commun (Camb); 2013 Mar; 49(21):2130-2. PubMed ID: 23386213
[TBL] [Abstract][Full Text] [Related]
19. Novel tacrine-8-hydroxyquinoline hybrids as multifunctional agents for the treatment of Alzheimer's disease, with neuroprotective, cholinergic, antioxidant, and copper-complexing properties.
Fernández-Bachiller MI; Pérez C; González-Muñoz GC; Conde S; López MG; Villarroya M; García AG; Rodríguez-Franco MI
J Med Chem; 2010 Jul; 53(13):4927-37. PubMed ID: 20545360
[TBL] [Abstract][Full Text] [Related]
20. Metal Ions in Alzheimer's Disease: A Key Role or Not?
Liu Y; Nguyen M; Robert A; Meunier B
Acc Chem Res; 2019 Jul; 52(7):2026-2035. PubMed ID: 31274278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
